Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma
NCT05677490Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2023
- Primary completion
- Nov 2028
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastroesophageal adenocarcinoma, esophageal adenocarcinoma (EAC), gastric adenocarcinoma, sponsored by Cancer and Leukemia Group B. Started Jan 2023; status: recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastroesophageal adenocarcinomaesophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT05677490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677490.